Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01406821 · ClinicalTrials.gov registry record · NA

Treatment of Acute and Chronic Ligament and Tendon Injuries With Platelet Rich Plasma

A NA study, sponsored by Stanford University.

Completed
Registry status
NA
Development phase
30
Enrollment target

NCT01406821: Completed NA study, sponsored by Stanford University.

NCT01406821 is a NA study that has completed, run by Stanford University. The registered enrollment target is 30 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT01406821, a NA study, has completed, sponsored by Stanford University.

COMPLETED
Registry status
NA
Development phase
30 participants
Enrollment target

Study Summary

Platelet rich plasma has been used in previous studies to stimulate faster healing of torn ligaments and tendons in order to help reduce pain and restore normal function. This study aims to prove that non-operative treatment of acute and chronic ligament and tendon injuries with platelet rich plasma will reduce the time needed for participants to heal these injuries and restore function. We are currently enrolling patients with PATELLAR TENDON INJURIES in the KNEE.

Interventions

  • PROCEDURE Ultrasound-guided platelet-rich-plasma (PRP) injection
  • PROCEDURE Ultrasound-guided dry needling

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2009-08
Est. Completion 2019-03-15
Phase NA
Stanford University

1,744 total trials

What the finished NCT01406821 record still lists

NCT01406821 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).

The record links to 0 conditions, and to 2 interventions - of which Ultrasound-guided platelet-rich-plasma (PRP) injection is the first listed.

NCT01406821 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT01406821 about?

NCT01406821 is a clinical study titled "Treatment of Acute and Chronic Ligament and Tendon Injuries With Platelet Rich Plasma". Platelet rich plasma has been used in previous studies to stimulate faster healing of torn ligaments and tendons in order to help reduce pain and restore normal function. This study aims to prove that non-operative treatment of acute and chronic ligament and tendon injuries with platelet rich plasma...

What is the current status of trial NCT01406821?

This trial is currently completed. It is a NA study. The enrollment target is 30 participants. The study started on 2009-08. Estimated completion is 2019-03-15.

What interventions are being tested in trial NCT01406821?

The interventions under investigation include: Ultrasound-guided platelet-rich-plasma (PRP) injection (PROCEDURE), Ultrasound-guided dry needling (PROCEDURE).

Who is sponsoring clinical trial NCT01406821?

This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT01406821's enrollment target sits among peer trials

30 1593rd of 2000 higher than 299 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00977977 · 30 participants · Phase 2

    Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy

  • NCT01459107 · 30 participants · Phase 2

    Human Upper Extremity Allotransplantation

  • NCT01666080 · 30 participants · NA

    Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)

  • NCT01720836 · 30 participants · Phase 1

    Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01406821, the US trial registry maintained by the National Library of Medicine. NCT01406821 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.